Key points from article :
SENISCA secured £1.3M for the development of its anti-ageing technology.
Aimed at enabling people to live healthy lives for longer.
Long term vision to deliver innovative, effective pharmaceutical interventions to treat age-related chronic diseases.
Investment round was oversubscribed by £350k against target of £950k.
Takes old or senescent cells and effectively resets the cellular ageing clock.
New investment will enable the company to further develop the potential medical applications towards clinical validation.
Will also develop anti-ageing cosmeceuticals, supported by a recent £240k grant award from Innovate UK.
“Positioning SENISCA as a global leader in the development of senotherapeutics," - Kirsty Semple, Chief Executive Officer.
"RNA biology expertise and world class laboratory facilities place us amongst the front runners in development of drugs that target mRNAs."
